drugset
drugset / Trial / NCT04081259

LY3214996 in Patients With AML Who Are Not Candidates for Standard Therapy

NCT04081259 ↗

Phase 1 Completed 17 enrolled Dana-Farber Cancer Institute Eli Lilly and Company · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This research study is evaluating a targeted therapy as a possible treatment for acute myeloid leukemia (AML) that has returned or not responded to standard treatment.

Timeline

Start
2020-07-15
Primary completion
2023-08-03
Completion
2023-08-26

Drugs

EvaluationDrugModalityDoseRoute
Subject TEMUTERKIB Small molecule — Oral

Indications

acute myeloid leukemia